

# HIV integrase inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/H308C7BED9D2EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: H308C7BED9D2EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "HIV integrase inhibitors - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in HIV integrase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### HIV integrase inhibitors Understanding

#### HIV integrase inhibitors: Overview

Retroviral integrase (IN) is an enzyme produced by a retrovirus (such as HIV) that integrates—forms covalent links between—its genetic information into that of the host cell it infects. Integrase inhibitors affect the way HIV works in the body.

Function –HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. The main function of IN is to insert the viral DNA into the host chromosomal DNA, a step that is essential for HIV replication. Integration is a 'point of no return' for the cell, which becomes a permanent carrier of the viral genome (provirus). Integration is in part responsible for the persistence of retroviral infections.[citation needed] After integration, the viral gene

expression and particle production may take place immediately or at some point in the future, the timing of which depends on the activity of the chromosomal locus hosting the provirus.

HIV integrase inhibitors- Integrase inhibitors rely on the fact that HIV needs integrase to replicate. These drugs stop HIV from being able to make integrase. Without the help of this enzyme, HIV can't take over the T cells to copy itself.

### HIV integrase inhibitors Emerging Drugs Chapters

This segment of the HIV integrase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### HIV integrase inhibitors Emerging Drugs

#### Cabotegravir: ViiV Healthcare

Cabotegravir (CAB), an analog of dolutegravir, prevents viral DNA integration into the host genome and inhibits HIV replication. CAB is being developed for both HIV treatment and HIV prevention. It is currently in phase 3 of clinical development.

#### Bictegravir : Gilead Sciences

The bictegravir contained in Biktarvy® is an integrase strand transfer inhibitor that prevents the replication of the HIV 1 virus by blocking HIV-1 integrase, an enzyme required for replication of HIV virus. It also blocks the formation and propagation of HIV-1 provirus. It is currently in phase 1 of clinical trials.

Further product details are provided in the report.....

### HIV integrase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different HIV integrase inhibitors drugs segregated based on following parameters that define the scope of the report,

such as:

Major Players working on HIV integrase inhibitors

There are approx. 3+ key companies which are developing the HIV integrase inhibitors. The companies which have their HIV integrase inhibitors drug candidates in the most advanced stage, i.e. phase III include, ViiV Healthcare.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

HIV integrase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HIV integrase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HIV integrase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

*HIV integrase inhibitors - Pipeline Insight, 2022*

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HIV integrase inhibitors drugs.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence HIV integrase inhibitors R&D. The therapies under development are focused on novel approaches for HIV integrase inhibitors.

## HIV integrase inhibitors Report Insights

HIV integrase inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## HIV integrase inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

## Current Scenario and Emerging Therapies:

How many companies are developing HIV integrase inhibitors drugs?

How many HIV integrase inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for HIV integrase inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HIV integrase inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for HIV integrase inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

ViiV Healthcare

Gilead Sciences

GlaxoSmithKline

## Key Products

Cabotegravir injection

Bictegravir

GSK 3640254

## Contents

Introduction

Executive Summary

HIV integrase inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

HIV integrase inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

HIV integrase inhibitors companies' collaborations, Licensing, Acquisition -Deal Value

Trends

HIV integrase inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Cabotegravir injection : ViiV Healthcare

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Bictegravir: Gilead Sciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

MRTX-1133: Mirati Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

HIV integrase inhibitors Key Companies

HIV integrase inhibitors Key Products

HIV integrase inhibitors- Unmet Needs

HIV integrase inhibitors- Market Drivers and Barriers

HIV integrase inhibitors- Future Perspectives and Conclusion

HIV integrase inhibitors Analyst Views

HIV integrase inhibitors Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for HIV integrase inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for HIV integrase inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: HIV integrase inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/H308C7BED9D2EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H308C7BED9D2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970